Conferences - Results from #8000

ASCO 2017: A 17-gene panel for prediction of adverse surgical pathology in the setting of MRI-guided prostate biopsy June 6, 2017

ASCO 2017: Association of loss of tumor suppressor ZFP36 with lethal prostate cancer June 6, 2017

ASCO 2017: Association of androgen receptor status in plasma DNA with outcome on enzalutamide or abiraterone or castration resistant prostate cancer June 6, 2017

ASCO 2017: Ten-year overall and prostate cancer specific mortality in high-risk patients after high-dose-rate brachytherapy combined with external beam radiation therapy (HDR-BT/EBRT) compared with EBRT alone June 6, 2017

ASCO 2017: Effect of Ga-68 PSMA-11 PET on management in patients with recurrent prostate cancer June 6, 2017

ASCO 2017: Whole blood androgen receptor variant expression and overall survival in metastatic castrate resistant prostate cancer June 6, 2017

ASCO 2017: Astellas and Seattle Genetics Announce Updated Enfortumab Vedotin Phase 1 Data in Metastatic Urothelial Cancer June 6, 2017

ASCO 2017: The plasma lipidome in castration-resistant prostate cancer June 6, 2017

ASCO 2017: Combination of PDL-1 and PARP inhibition in an unselected population with metastatic castrate-resistant prostate cancer (mCRPC) June 6, 2017

ASCO 2017: Incidence of intrathoracic metastases detected by 68Ga-PSMA-11 PET in early stage prostate cancer June 6, 2017

ASCO 2017: Clinical implications of the 2012 US Preventive Services Task Force PSA screening recommendation in prostate cancer diagnoses and 5-year survival at a Minnesota safety net health care system June 6, 2017

ASCO 2017: Circulating tumour cells and survival in abiraterone and enzalutamide treated patients with castration-resistant prostate cancer June 6, 2017

ASCO 2017: Predictors of post-surgical race-specific prostate cancer progression June 6, 2017

ASCO 2017: Post hoc analysis of a phase III study to test the association between circulating methylated glutathione s transferase (mGSTP1) DNA levels and response to docetaxel in metastatic castration resistant prostate cancer June 6, 2017

ASCO 2017: The aggressive variant prostate carcinoma molecular signature (-MS) and platinum-sensitivity in castration resistant prostate cancer June 6, 2017

ASCO 2017: Identification of a CTC-based gene expression signature predicting resistance to abiraterone and enzalutamide in mCRPC June 6, 2017

ASCO 2017: Baseline CTC subtype to predict outcomes on mCRPC patients receiving enzalutamide compared to abiraterone June 6, 2017

ASCO 2017: Stereotactic ablative radiation therapy for the treatment of oligometastatic prostate cancer June 6, 2017

ASCO 2017: Adjuvant androgen deprivation (AD) +/- mitoxantrone + prednisone (MP) in patients with high-risk prostate cancer (PC) post radical prostatectomy (RP): Phase III intergroup trial S9921 June 6, 2017

ASCO 2017: Clinical outcome of metastatic castration-resistant prostate cancer patients with a post-treatment circulating tumor cell of 0 vs CTC > 0: Post hoc analysis of COU-AA-301 June 6, 2017

Page 401 of 537